Julie Iwashita

Vice President of Clinical Operations

Julie brings more than 25 years of experience leading clinical development programs through successful submissions and marketing approvals.  Previously Julie was executive director, clinical operations at Kodiak Sciences, a company focused on developing therapies for retinal disease.  Prior to Kodiak, she served as executive director of clinical development at Laguna Pharmaceuticals and, prior to that, at Sorbent Therapeutics.  Prior to Sorbent, Iwashita was senior director of clinical development at MAP Pharmaceuticals and held positions at Proteolix, through its acquisition by Onyx Pharmaceuticals, and at Affymax.  She has also managed clinical programs at Genitope, Aviron (through acquisition by MedImmune), Amgen and Syntex in various therapeutic areas including renal, cardiovascular, and oncology.  Julie holds a bachelor’s degree in human biology from Stanford University.